Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of vandetanib and
fulvestrant; to find the maximum tolerated dose of these two drugs; and to evaluate response
rate and assess toxicity of this combination.